Genomic Medicine
- 1 November 2014
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 21 (6) , 548-553
Abstract
Our perception of the mechanism by which single genes can cause disease is evolving. This has led to the understanding of the pathophysiological basis of common diseases. Genomic Medicine continues to contribute to the understanding of the molecular basis of disease. Medicine has strived to achieve the goal of tailoring interventions to individual variations in risk and treatment response and advances in medical genomics will facilitate this process. Relevant to present-day practice is the use of genomic information to classify individuals according to disease susceptibility or expected responsiveness to a pharmacologic treatment and to provide targeted interventions. By investigating the genetic profile of individuals, medical professionals are able to select patients and use the information obtained to plan out a course of treatment that is much more in step with the way their body works. However, society is concerned about the effect genetic knowledge will have on ethnic or racial groups. Currently, the Health Insurance Portability and Accountability Act prohibits discrimination based on genetics. There is a need to increase the understanding of the social and ethical challenges that genomics information may pose to clinicians and scientists. This review is not meant to be exhaustive; rather, clinically relevant examples are used to illustrate how genomic medicine can facilitate the provision of molecular diagnostic methods that improve drug therapy. Finally, the rapid pace of change in genomics may likely make my conclusions today obsolete tomorrow.Keywords
This publication has 36 references indexed in Scilit:
- Genomics and Drug ResponseNew England Journal of Medicine, 2011
- International network of cancer genome projectsNature, 2010
- HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillinNature Genetics, 2009
- A HapMap harvest of insights into the genetics of common diseaseJournal of Clinical Investigation, 2008
- Mapping and sequencing of structural variation from eight human genomesNature, 2008
- HLA-B*5701 Screening for Hypersensitivity to AbacavirNew England Journal of Medicine, 2008
- Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: Cohort study using data from the UK General Practice Research DatabaseBritish Journal of Clinical Pharmacology, 2005
- A map of human genome sequence variation containing 1.42 million single nucleotide polymorphismsNature, 2001
- New genetics means no new ethicsNature, 1993
- Liver damage from flucloxacillin, cloxacillin and dicloxacillinJournal of Hepatology, 1992